 Johnson Johnson NYSE: JNJ has walked away from a 1.6 billion blood cancer candidate deal with Argenx SE NASDAQ: ARGX for the CD70-targeting cusatuzumab. The pair first came together to develop the med across various blood cancers and disorders in December 2018. 